NCT06993506View on ClinicalTrials.gov

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

October 31, 2027

Conditions
HER2-negative Breast CancerRecurrenceMetastasis
Interventions
DRUG

SKB264 Monotherapy or Combination Therapy

The interventions in this study comprised SKB264 monotherapy or combination therapy involving SKB264. The specific combination regimens were determined based on real-world clinical practice.

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER